Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Update on CARTITUDE-1: CAR-T in RRMM

Jesús Berdeja • 26 May 2020
ASCO 2020
Multiple Myeloma Ciltacabtagene autoleucel
CARTITUDE-1

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on CARTITUDE-1 (NCT03548207), a Phase Ib/II study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús Berdeja

1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
1:19
ASCO 2020: updates in myeloma
Jesús Berdeja • 26 May 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals